HOME | CONTACT US

CANCER - A new anti-cancer strategy

Cancer is characterized by either the uncontrolled growth of cells or the failure of cells to die normally. Often, cancer cells spread (metastasize) to distant parts of the body, where they can form new tumors. Treatment is often uncomfortable and intolerable.   

BioMonde's response!
The Global
Burden of Cancer

The World Cancer Report tells us that cancer rates are set to increase at an alarming rate globally, and could further increase by 50% to 15 million new cases in the year 2020. In the year 2000, malignant tumors were responsible for 12 per cent of the nearly 56 million deaths worldwide from all causes. In many countries, more than a quarter of deaths are attributable to cancer. In 2000, 5.3 million men and 4.7 million women developed a malignant tumor and altogether 6.2 million died from the disease.

Problems associated with Cancer treatments 
kills healthy cells;
bone marrow(makes blood cells);
hair follicles;
lining of the mouth;
digestive system;
surgical complications;
hemoglobin
discomfort.

 



Common Cancer Treatments

Surgery
Radiation Therapy
Chemotherapy
Holistic Therapy

 

Cancer Cells Dividing

cancer cell division

  

  

Dr. Jane Cooke Wright

Discovered Chemotherapy Treatment for Cancer

dr_jane_cooke_wright

 

  

  

Development of a optimized, safe, effective and affordable class of novel anti-cancer  umbelliferone derivatives (4-meythylumbellierone - 4MU), and anti-neoplasm derivatives.
4-mu


  • 4MU as a adjunct therapy in the management of metastatic, liver, prostate, pancreatic, breast, brain, melanoma, and other cancers.
  • 4MU as a adminiculum to Gemcitabine and other anticancer chemotherapy treatments;
  • 4MU as a anticancer chemotherapy prophylaxis;
  • anti-neoplasm as a adjunct therapy to 4MU;
  • anti-neoplasm as a adjunct therapy in the management of metastatic, prostate, pancreatic, liver, breast, brain, melanoma, kaposi's sarcoma and other cancers.

BioMonde is focused on preventing the progression of cancers and to improving the tolerability and effectiveness of chemotherapy drugs. According to cancer research, hyaluronan synthase (HA) over expression is very much implicated in malignant transformation and tumor progression, especially metastasis cancers. By preventing the overexpression of HA it is possible to slow or halt the progression of many Cancer's, and significantly improve the effectiveness and tolerability of anticancer drugs. Umbelliferone derivatives (4-meythylumbellierone) are scientifically recognized as potent HA over expression inhibitors, that help prevent tumor metastasis based on its inhibitory effect on hyaluronan synthases as a adminiculum in cancer chemotherapy.

Anti-neoplasm derivatives administered in combination Umbelliferone derivatives (4-meythylumbellierone) exert a potent synergy effect that greatly improves the anti-cancer effects, especially metastasis cancer. Anti-neoplasm derivations may also be administered independently of Umbelliferone derivatives (4-meythylumbellierone). 

Consequently, BioMonde's approach to cancer healthcare means that patients now have access to a New Anti-Cancer Oncology strategy, that improves the effectiveness and also lessens the discomfort associated with existing anticancer chemotherapies.

REFERENCE MATERIAL

Published and  Peer Reviewed Studies click-here


View our product pipeline click-here

Products containing umbelliferone derivatives (4-Methylumbelliferone) click-here

HEPARVIT™ ProCELL

Products containing anti-neoplasm derivatives click-here

ExCELL

 



Hyaluronan

hyaluronan


  

  

  

  

Medical research...........

Indicates that umbelliferone derivatives (4-meythylumbellierone) administered as a preventive or management therapy for cancer, or administered as a adjunct therapy to gemcitabine and other anti-cancer drugs:

  • Can reduce tumor metastasis to the liver by 30% or more;
  • Targets pancreatic (KP1-NL) and other cancer cells and decreases the cell surface HA, which prevents the cancer from progressing;
  • Targets pancreatic (KP1-NL) and other cancer cells and decreases the cell surface HA, which exposes the cells to anti-cancer drugs for destruction.
  • Decreases the size of the primary and metastatic tumors more than gemcitabine alone;
  • Strongly suggests that a combination of gemcitabine and umbelliferone derivatives (4-meythylumbellierone)  and  is effective against human pancreatic and other cancer cells;
  • Reduces elevated liver enzymes associated with chemotherapy toxicity (drug induced Hepatitis);
  • Improves red blood cell and platelet regeneration; tiredness, appetite, and digestive functions;
  • Greatly improves effectiveness and tolerability when taken as a prophylaxis before commencing anticancer treatment.

Indicates that the anti-neoplasm derivatives:

  •  Promote the generation of the bodies own cancer killing cells;
  • Help rebuild a damaged immune system.